Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Patent number: 7029866Abstract: The invention is directed to a method of diagnosis of the existence and/or the pathological developmental stage and/or the grade of malignancy of carcinomas and/or sarcomas in mammals characterized by the preparation of a body sample of said mammals and the determination of the overexpression of the protein Nup88 in said sample and to antibodies suitable for performing the same.Type: GrantFiled: October 10, 2000Date of Patent: April 18, 2006Inventors: Hanswalter Zentgraf, Susanne Franz, Angel Alonso, Nerea Martinez
-
Patent number: 7030227Abstract: This application describes the cloning of p63, a gene at chromosome 3q27-29, that bears homology to the tumor suppressor p53. The p63 gene encodes at least six different isotypes. p63 was detected in a variety of human and mouse tissue and demonstrates remarkably divergent activities, such as the ability to transactivate p53 reporter genes and induce apoptosis. Isotopes of p63 lacking a transactivation domain act as dominant negatives towards the transactivation by p53 and p63.Type: GrantFiled: October 15, 1998Date of Patent: April 18, 2006Assignee: President & Fellows of Harvard CollegeInventors: Frank McKeon, Annie Yang
-
Patent number: 7025962Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: April 10, 2000Date of Patent: April 11, 2006Assignee: Schering CorporationInventors: Daniel M. Gorman, Troy D. Randall, Albert Zlotnik
-
Patent number: 7012134Abstract: The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.Type: GrantFiled: February 5, 2002Date of Patent: March 14, 2006Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Paul E. Young
-
Patent number: 7008772Abstract: Compounds and methods for diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. The inventive polypeptides may be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.Type: GrantFiled: July 14, 1998Date of Patent: March 7, 2006Assignee: Corixa CorporationInventors: Jiangchun Xu, Davin C. Dillon
-
Patent number: 6979726Abstract: The present invention relates to new fusion proteins which consist of a tumor-associated targeting element preferentially a monoclonal antibody or a fragment thereof recognizing a molecule which is preferentially expressed on human tumor cells such as the human epidermal growth factor receptor (EGFR), and a biologically active ligand such as a growth and/or differentiation factor. The resulting fusion protein may be used to deliver the biologically active ligand to a specific target cell or tissue. The new immunoconjugates can be used in tumor therapy.Type: GrantFiled: December 23, 1994Date of Patent: December 27, 2005Assignee: Merck Patent GmbHInventors: Ilka von Hoegen, Uwe Hofmann, Carlota-Silvia Jaggle, Wolfgang Strittmatter, Jörg Stadlmüller, Siegfried Matzku
-
Patent number: 6969518Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.Type: GrantFiled: April 15, 2002Date of Patent: November 29, 2005Assignee: Corixa CorporationInventors: Raymond L. Houghton, Paul R. Sleath, David H. Persing
-
Patent number: 6969517Abstract: The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies, when coupled to the appropriate moiety, may be used in the diagnosis, prognosis and treatment of cancer.Type: GrantFiled: May 3, 2002Date of Patent: November 29, 2005Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin-Ming Lo, Susan X. Qian
-
Patent number: 6965017Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.Type: GrantFiled: July 3, 2001Date of Patent: November 15, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Yutaka Kawakami, Steven A. Rosenberg
-
Patent number: 6962980Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer.Type: GrantFiled: April 4, 2001Date of Patent: November 8, 2005Assignee: Corixa CorporationInventors: Jennifer L. Mitcham, Gordon E. King, Paul A. Algate
-
Patent number: 6955717Abstract: The present invention provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab, and subsets thereof, and methods of using them.Type: GrantFiled: April 29, 2002Date of Patent: October 18, 2005Assignees: Medimmune Inc., Bowie State UniversityInventors: Leslie S. Johnson, Bradford Braden
-
Patent number: 6955885Abstract: A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the regulation of electrolyte imbalances which can lead to renal, bone and heart diseases and osteoporosis and Paget's Disease. Antagonists against such polypeptides and their use in the regulation of electrolyte imbalances which can lead to hypocalcemia and osteoporosis are also disclosed. Use of the stanniocalcin-alpha sequence as a diagnostic to detect diseases or the susceptibility to diseases related to a mutated form of stanniocalcin-alpha sequences is also disclosed.Type: GrantFiled: April 18, 2003Date of Patent: October 18, 2005Assignee: Human Genome Sciences, Inc.Inventors: Henrik S. Olsen, Robert D. Fleischmann
-
Patent number: 6936424Abstract: The invention provides a wide range of methods and compositions for detecting and treating breast cancer in an individual. Specifically, the invention provides target breast cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of breast cancer. The target breast cancer-associated protein may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of breast cancer in an individual. In addition, the invention provides methods utilizing the breast cancer-associated proteins either as targets for treating breast cancer or as indicators for monitoring the efficacy of such a treatment.Type: GrantFiled: November 10, 2000Date of Patent: August 30, 2005Assignee: Matritech, Inc.Inventors: Brynmor Watkins, Robert P. Szaro
-
Patent number: 6936706Abstract: An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid.Type: GrantFiled: September 6, 2001Date of Patent: August 30, 2005Inventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson, Eduardo A. Padlan
-
Patent number: 6926896Abstract: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.Type: GrantFiled: December 13, 1994Date of Patent: August 9, 2005Assignee: Aventis Pharma Deutschland GmbHInventors: Klaus Bosslet, Gerhard Seemann, Hans Harald Sedlacek, Bernhard Auerbach
-
Patent number: 6914130Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: August 14, 2001Date of Patent: July 5, 2005Assignee: Genentech, Inc.Inventors: Wei-Qiang Gao, Audrey Goddard, Austin L. Gurney, Colin K. Watanabe, William I. Wood
-
Patent number: 6911532Abstract: The invention relates generally to compositions of and methods for obtaining and using a polypeptide other than BCL-2 that affects programmed vertebrate cell death. The invention relates as well to polynucleotides encoding those polypeptides, recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, and recombinant polypeptides. The invention further provides methods for using the isolated, recombinant polypeptides in assays designed to select and improve substances capable of altering programmed cell death for use in diagnostic, drug design and therapeutic applications.Type: GrantFiled: September 12, 2001Date of Patent: June 28, 2005Assignee: The Reagents of the University of MichiganInventors: Craig B. Thompson, Lawrence H. Boise, Gabriel Nuñez
-
Patent number: 6897295Abstract: This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide, a process for the production of the novel polypeptide, an antibody which recognizes the novel polypeptide, an oligonucleotide complementary to the novel DNA and a novel screening method. Particularly this invention provides a novel polypeptide which is Fas ligand or a fragment thereof. This novel polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This novel polypeptide is obtained by identifying a DNA fragment which encodes the novel polypeptide, transforming a desired host with a recombinant DNA molecule which contains the DNA fragment and purifying the novel polypeptide produced by the resulting transformant.Type: GrantFiled: July 16, 1996Date of Patent: May 24, 2005Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu Nagata, Takashi Suda, Tomohiro Takahashi, Norio Nakamura
-
Patent number: 6893638Abstract: The present invention relates to methods for treating B cell lymphoma using CD80-specific antibodies.Type: GrantFiled: January 12, 2001Date of Patent: May 17, 2005Inventors: Darrell R. Anderson, Peter Brams, Nabil Hanna, William S. Shestowsky, Cheryl Heard
-
Patent number: 6891022Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to PRO201, PRO308 or PRO309 polypeptides. The invention further relates to compositions and method for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based in part on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targents for the diagnosis and/or treatment (including prevention) of certain tumors (e.g., cancer) and may act as predictors of the prognosis of tumor treatment.Type: GrantFiled: April 23, 1999Date of Patent: May 10, 2005Assignee: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu
-
Patent number: 6890724Abstract: The invention relates to methods and compositions for the isolation of neural progenitor cells.Type: GrantFiled: September 25, 1996Date of Patent: May 10, 2005Assignee: California Institute of TechnologyInventors: David J. Anderson, Li-Ching Lo
-
Patent number: 6887474Abstract: The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the formation of a platelet-mediated thrombus-causing vessel occlusion.Type: GrantFiled: November 12, 1999Date of Patent: May 3, 2005Assignee: ViRexx Medical CorporationInventors: Michael William Stewart, Roland Henryk Person, Antoine Noujaim
-
Patent number: 6884594Abstract: The present invention discloses Growth Factor HTTER36 polypeptides and polynucleotides encoding such polypeptides. Also disclosed are antibodies and fragments thereof that specifically bind to such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include stimulating cellular growth and differentiation, bone formation and wound healing. Also disclosed are antagonists against such polypeptide and their use as a therapeutic to treat neoplasia and to prevent the formation of extracellular matrix molecules in the liver and lung. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the invention.Type: GrantFiled: April 8, 2002Date of Patent: April 26, 2005Assignee: Human Genome Sciences, Inc.Inventors: Daniel R. Soppet, Haodong Li
-
Patent number: 6881405Abstract: The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.Type: GrantFiled: June 15, 1999Date of Patent: April 19, 2005Assignee: AltaRex Medical Corp.Inventors: Beatrice Leveugle, Ragupathy Madiyalakan, Antoine A. Noujaim, Birgit Schultes
-
Patent number: 6863892Abstract: A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.Type: GrantFiled: August 22, 2001Date of Patent: March 8, 2005Assignee: Agensys, Inc.Inventors: Mary Faris, Rene S. Hubert, Arthur B. Raitano, Daniel E. H. Afar, Elana Levin, Pia Challita-Eid, Aya Jakobovits
-
Patent number: 6849417Abstract: A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.Type: GrantFiled: September 28, 2000Date of Patent: February 1, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Vadim N. Gladyshev, Dolph L. Hatfield, Kuan-Teh Jeang, Alan Diamond, John C. Wootton
-
Patent number: 6843990Abstract: The invention provides monoclonal antibodies against decoy receptor 3 (DcR3), hybridomas producing said antibodies, kits containing said monoclonal antibodies and uses of the hybridomas, antibodies and kits for the detection of DcR3-associated diseases, as well as for the treatment and/or prevention of DcR3-associated diseases.Type: GrantFiled: December 3, 2001Date of Patent: January 18, 2005Assignee: Anawrahta Biotech Co.Inventors: Mai Shen-Chih, Liu Shih-Jen
-
Patent number: 6835370Abstract: The invention features a method for diagnosing and inhibiting growth of a malignant neoplasm in a mammal by contacting a cell or a bodily fluid of the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide. Methods of immunization to generate an HAAH-specific immune response are also within the invention.Type: GrantFiled: May 17, 2001Date of Patent: December 28, 2004Assignee: Rhode Island HospitalInventors: Jack R. Wands, Suzanne M. de la Monte, Alan H. Deutch, Hossein A. Ghanbari
-
Patent number: 6824775Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expressing or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.Type: GrantFiled: April 4, 2001Date of Patent: November 30, 2004Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 6824993Abstract: The present invention relates to PSGR, a novel prostate specific gene with homology to a G-protein coupled receptor overexpressed in prostate cancer. More specifically, the invention relates to PSGR polynucleotides and the polypeptides encoded by these polynucleotides, and the use of PSGR polynucleotides and polypeptides for detecting disorders of the reproductive system, including disorders of the prostate, particularly the presence of cancer. This invention relates to PSGR polynucleotides and polypeptides as well as vectors, host cells, antibodies directed to PSGR polynucleotides and polypeptides and recombinant and synthetic methods for producing the same. Also provided are methods for diagnosing, treating, preventing, and/or prognosing disorders related to the prostate, including cancer.Type: GrantFiled: October 2, 2001Date of Patent: November 30, 2004Assignee: Human Genome Sciences, Inc.Inventors: Daniel R. Soppet, Yi Li, Craig A. Rosen, Steven M. Ruben
-
Patent number: 6822080Abstract: Substantially pure human cyclin-dependent kinase-like proteins PITALRE and PISSLRE and isolated protein complexes that comprise PITALRE or PISSLRE are disclosed. Isolated nucleic acid molecule that encode PITALRE or PISSLRE, or a fragment thereof; recombinant expression vectors that comprise nucleic acid sequence that encode PITALRE or PISSLRE; and host cells that comprise such recombinant expression vectors are disclosed. Oligonucleotide molecules that consist of a nucleotide sequence complimentary to a portion of the nucleotide sequence that encodes PITALRE or PISSLRE are disclosed. Antibodies which bind to epitopes on PITALRE or PISSLRE are disclosed. Nucleic acid molecules that comprise a nucleotide sequence that encodes phosphorylation deficient PITALRE, or a phosphorylation deficient PI SSLRE; recombinant vectors and pharmaceutical compositions that comprise such nucleotide sequences are also disclosed. Methods of identifying compounds which inhibit PITALRE activity are disclosed.Type: GrantFiled: May 16, 2000Date of Patent: November 23, 2004Assignee: Thomas Jefferson UniversityInventor: Antonio Giordano
-
Patent number: 6818213Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.Type: GrantFiled: July 12, 1999Date of Patent: November 16, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
-
Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
Patent number: 6805862Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglio-side-specific antibody attached to a carrier.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 2004Assignee: Sloan-Kattering Institute For Cancer ResearchInventors: Paul B. Chapman, Alan N. Houghton -
Patent number: 6800738Abstract: Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.Type: GrantFiled: November 2, 2000Date of Patent: October 5, 2004Assignee: Genentech, Inc.Inventors: Paul J. Carter, Leonard G. Presta
-
Patent number: 6800737Abstract: The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the Survivin family of proteins, methods for identifying agents that block Survivin mediated inhibition of cellular apoptosis, methods of using agents that block Survivin mediated inhibition or Survivin expression to modulate biological and pathological processes, and methods of assaying Survivin activity.Type: GrantFiled: May 6, 2002Date of Patent: October 5, 2004Assignee: Yale UniversityInventor: Dario C. Altieri
-
Patent number: 6797812Abstract: The invention relates to an isolated nucleic acid molecule encoding a caspase-14 polypeptide or functional fragment thereof, a vector that contains the nucleic acid molecule and a host cell that contains the vector. The invention also relates to an isolated gene encoding caspase-14, as well as functional fragments thereof. The gene or nucleic acid molecule can include single or double stranded nucleic acids corresponding to coding or non-coding strands of the caspase-14 nucleotide sequence. Isolated caspase-14 polypeptides or functional fragments thereof are also provided, as are antibodies that specifically bind thereto. In addition, the invention relates to methods of identifying compounds that modulate caspase-14 activity.Type: GrantFiled: November 20, 2001Date of Patent: September 28, 2004Assignee: Thomas Jefferson UniversityInventors: Emad S. Alnemri, Teresa Fernandez-Alnemri
-
Patent number: 6787153Abstract: A human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, an isolated DNA encoding the antibody, and a hybridoma producing the antibody. An anti-cancer formulation comprising the monoclonal antibody bonded to the surface of a liposome enclosing an anti-cancer agent or toxin is also provided.Type: GrantFiled: December 21, 1999Date of Patent: September 7, 2004Assignee: Mitsubishi Chemical CorporationInventors: Saiko Hosokawa, Toshiaki Tagawa, Yoko Hirakawa, Norihiko Ito, Kazuhiro Nagaike
-
Patent number: 6783758Abstract: The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.Type: GrantFiled: July 11, 2001Date of Patent: August 31, 2004Assignee: Rhode Island HospitalInventors: Jack R. Wands, Suzanne M. de la Monte, Nedim Ince, Rolf I. Carlson
-
Patent number: 6783945Abstract: This invention provides an isolated vertebrate nucleic acid molecule the bcl-6 locus. This invention also provides an isolated human nucleic acid molecule of bcl-6 locus. This invention further provides a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic acid molecule of bcl-6 locus. This invention provides an isolated vertebrate nucleic acid molecule of bcl-6 operatively linked to a promoter of RNA transcription. This invention provides a vector which comprises the nucleic acid molecule of bcl-6 locus. This invention provides a host vector system for the production of a polypeptide encoded by bcl-6 locus, which comprises the vector of bcl-6 locus in a suitable host. This invention provides a polypeptide encoded by the isolated vertebrate nucleic acid molecule of bcl-6 locus. This invention provides an antibody capable of binding to polypeptide encoded by bcl-6 locus.Type: GrantFiled: January 16, 2001Date of Patent: August 31, 2004Assignees: The Trustees of Columbia University in the City of New York, Sloan-Kettering Institute for Cancer ResearchInventors: Raju S. K. Chaganti, Riccardo Dalla-Favera
-
Patent number: 6774217Abstract: The present invention relates to nucleotide sequences of FHIT genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The FHIT gene sequence is mutated in diseases involving cell overproliferation, particularly malignancies of the digestive tract. The present invention further relates to the use of FHIT genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with cell overproliferation.Type: GrantFiled: November 21, 2000Date of Patent: August 10, 2004Assignee: Thomas Jefferson UniversityInventors: Carlo M. Croce, Frances Kay Huebner
-
Patent number: 6774216Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: GrantFiled: April 4, 2002Date of Patent: August 10, 2004Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Craig A. Rosen, David W. LaFleur
-
Patent number: 6770450Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers.Type: GrantFiled: July 20, 1999Date of Patent: August 3, 2004Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6770445Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.Type: GrantFiled: February 25, 2000Date of Patent: August 3, 2004Assignee: Pacific Northwest Research InstituteInventors: Nathalie B. Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Patent number: 6767541Abstract: The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genetic profiles. These methods identify an important link between HER-2/neu overexpression and loss of growth inhibition by the TGF-&bgr; signaling pathway in cancer cells. Compositions as well as therapeutic and diagnostic methodologies based on this disclosure are provided.Type: GrantFiled: March 20, 2001Date of Patent: July 27, 2004Assignees: The Regents of the University of California, Amgen Inc.Inventors: Dennis J. Slamon, Cindy A. Wilson, Frank J. Calzone
-
Patent number: 6767996Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.Type: GrantFiled: May 17, 1993Date of Patent: July 27, 2004Assignee: Glaxo Wellcome Inc.Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
-
Patent number: 6764679Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.Type: GrantFiled: June 28, 2001Date of Patent: July 20, 2004Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, David Botstein, Kelly H. Dodge, Audrey Goddard, Austin L. Gurney, Kyung Jin Kim, David A. Lawrence, Robert Pitti, Margaret A. Roy, Daniel B. Tumas, William I. Wood
-
Patent number: 6759204Abstract: The invention concerns a method for early diagnosis of cancer in a patient which consists in identifying by any appropriate method the presence of autoantibodies directed against the Csk protein in a biological sample taken from said patient. The invention also concerns a kit for implementing said diagnostic method.Type: GrantFiled: December 15, 2000Date of Patent: July 6, 2004Assignee: Centre National de la Recherche Scientifique-CNRSInventors: Christine Benistant, Heliette Chapuis, Nicolas Mottet-Auselo, Serge Roche, Jean-François Bourgaux, Jean-Pierre Bali
-
Patent number: 6759518Abstract: The present invention relates to a single-chain, multiple antigen-binding molecule with diverse variable domains of a heavy and of a light chain of an immunoglobulin, which are connected in the form of a VH-VL construct, which are in turn connected together via a peptide, and to the preparation and use thereof as pharmaceutical or diagnostic aid.Type: GrantFiled: April 9, 1999Date of Patent: July 6, 2004Assignee: Vectron Therapeutics AGInventors: Roland Kontermann, Hans-Harald Sedlacek, Rolf Mueller
-
Patent number: 6747133Abstract: The invention provides novel tumor suppressor genes, methods for making and using these and related tumor suppressor genes and proteins and peptides, and nucleic acids encoding these and related tumor suppressor proteins and peptides.Type: GrantFiled: March 22, 2000Date of Patent: June 8, 2004Assignee: University Technologies International Inc.Inventors: Igor Garkavtsev, Karl Riabowol
-
Patent number: RE38916Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.Type: GrantFiled: November 18, 1999Date of Patent: December 6, 2005Assignees: The Johns Hopkins University, The University of Utah, The Cancer Institute, Zeneca LimitedInventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuka Nakamura, Andrew Thilveris, Raymond L. White